Core Insights - Eli Lilly's international president Patrik Jonsson expressed uncertainty regarding the U.S. Food and Drug Administration's new fast-track review process, indicating that it is too early to assess its implications for the company [1] Group 1 - The company is currently lacking clarity on the new fast-track review process implemented by the FDA [1] - Jonsson's comments suggest that the company is cautious about the potential impacts of this new regulatory approach [1]